26-03-2018
ericsphotography / iStockphoto.com
UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Indivior, generics, Suboxone, Alvogen, patent infringement, non-infringement, opioid addiction, ANDA,
US judge invalidates Pernix patents in Alvogen clash
28-08-2018
Indivior obtains court order to block generic Suboxone
18-06-2018
Indivior settles addiction drug dispute with Par
16-05-2018
Indivior settles generic dispute with Mylan
28-09-2017
Indivior to appeal court verdict over Suboxone Film patents
04-09-2017
